Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

An energetic tale of AMPK-independent effects of metformin.

Miller RA, Birnbaum MJ.

J Clin Invest. 2010 Jul;120(7):2267-70. doi: 10.1172/JCI43661. Epub 2010 Jun 23. Review.

2.

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B.

J Clin Invest. 2010 Jul;120(7):2355-69. doi: 10.1172/JCI40671. Epub 2010 Jun 23.

3.

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ.

Nature. 2013 Feb 14;494(7436):256-60. doi: 10.1038/nature11808. Epub 2013 Jan 6.

4.

Role of AMP-activated protein kinase in mechanism of metformin action.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE.

J Clin Invest. 2001 Oct;108(8):1167-74.

5.

Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.

Aw DK, Sinha RA, Xie SY, Yen PM.

Biochem Biophys Res Commun. 2014 May 16;447(4):569-73. doi: 10.1016/j.bbrc.2014.04.031. Epub 2014 Apr 13.

PMID:
24735537
6.

Revisiting the mechanisms of metformin action in the liver.

Viollet B, Foretz M.

Ann Endocrinol (Paris). 2013 May;74(2):123-9. doi: 10.1016/j.ando.2013.03.006. Epub 2013 Apr 10. Review.

7.
8.

AMP-activated protein kinase in metabolic control and insulin signaling.

Towler MC, Hardie DG.

Circ Res. 2007 Feb 16;100(3):328-41. Review.

9.

Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.

Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ.

Diabetes. 2002 Jul;51(7):2074-81.

10.

Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action.

Takashima M, Ogawa W, Hayashi K, Inoue H, Kinoshita S, Okamoto Y, Sakaue H, Wataoka Y, Emi A, Senga Y, Matsuki Y, Watanabe E, Hiramatsu R, Kasuga M.

Diabetes. 2010 Jul;59(7):1608-15. doi: 10.2337/db09-1679. Epub 2010 Apr 14.

11.

Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.

Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS.

Diabetes. 2008 Feb;57(2):306-14. Epub 2007 Oct 1.

12.

Metformin--mode of action and clinical implications for diabetes and cancer.

Pernicova I, Korbonits M.

Nat Rev Endocrinol. 2014 Mar;10(3):143-56. doi: 10.1038/nrendo.2013.256. Epub 2014 Jan 7. Review.

PMID:
24393785
13.

Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).

Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, Radovick S, Wondisford FE, He L.

J Biol Chem. 2014 Jul 25;289(30):20435-46.

14.

Regulation of glucose-6-phosphatase gene expression by insulin and metformin.

Mues C, Zhou J, Manolopoulos KN, Korsten P, Schmoll D, Klotz LO, Bornstein SR, Klein HH, Barthel A.

Horm Metab Res. 2009 Oct;41(10):730-5. doi: 10.1055/s-0029-1225360. Epub 2009 Jul 3.

PMID:
19579180
15.

Pharmacogenetic variation and metformin response.

Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao J, Ding L, Zhang J, Wen A.

Curr Drug Metab. 2013 Dec;14(10):1070-82. Review.

PMID:
24329113
16.

Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.

Ford RJ, Fullerton MD, Pinkosky SL, Day EA, Scott JW, Oakhill JS, Bujak AL, Smith BK, Crane JD, Blümer RM, Marcinko K, Kemp BE, Gerstein HC, Steinberg GR.

Biochem J. 2015 May 15;468(1):125-32. doi: 10.1042/BJ20150125.

17.

[Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].

Santomauro Júnior AC, Ugolini MR, Santomauro AT, Souto RP.

Arq Bras Endocrinol Metabol. 2008 Feb;52(1):120-5. Review. Portuguese.

18.

Current understanding of metformin effect on the control of hyperglycemia in diabetes.

An H, He L.

J Endocrinol. 2016 Mar;228(3):R97-106. doi: 10.1530/JOE-15-0447. Epub 2016 Jan 7. Review.

19.

Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation.

Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM.

Acta Physiol (Oxf). 2015 Mar;213(3):711-21. doi: 10.1111/apha.12421. Epub 2014 Nov 24.

PMID:
25382002
20.

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.

Boyle JG, Salt IP, McKay GA.

Diabet Med. 2010 Oct;27(10):1097-106. doi: 10.1111/j.1464-5491.2010.03098.x. Review.

PMID:
20854376

Supplemental Content

Support Center